Scientific article
English

Severe complications after intrathecal methotrexate (MTX) for treatment of primary central nervous system lymphoma (PCNSL)

Published inClinical Neurology and Neurosurgery, vol. 106, no. 2, p. 82-87
Publication date2004
Abstract

Primary central nervous system lymphoma (PCNSL) is a rare and highly malignant tumor with increasing incidence. Survival has improved with the use of nonsurgical treatment modalities, of which methotrexate (MTX)-based intrathecal chemotherapy has been an important option. Here, we describe devastating complications in three patients with diffuse large B-cell lymphomas. After intrathecal MTX therapy two patients died secondary to fulminant brain edema. A third patient developed severe dementia, gait disturbance and urinary incontinence due to leukencephalopathy. Since bulky disease was present in all three patients, CSF flow may have been impaired. This might have exposed adjacent tissue to prolonged toxic drug concentrations. Regarding the severe complications seen in these patients, it is useful to consider high-dose intravenous MTX treatment only in periventricular PCNSL.

Keywords
  • Adult
  • Aged
  • Antimetabolites
  • Antineoplastic/administration & dosage/pharmacokinetics/toxicity
  • Brain Edema/chemically induced/pathology
  • Brain Neoplasms/drug therapy/pathology
  • Cerebral Ventricle Neoplasms/drug therapy/pathology
  • Cerebral Ventricles/drug effects/pathology
  • Dementia/chemically induced/pathology
  • Encephalocele/chemically induced/pathology
  • Endoscopy
  • Fatal Outcome
  • Female
  • Humans
  • Injections
  • Spinal
  • Lymphoma
  • B-Cell/drug therapy/pathology
  • Lymphoma
  • Large B-Cell
  • Diffuse/drug therapy/pathology
  • Magnetic Resonance Imaging
  • Male
  • Methotrexate/administration & dosage/pharmacokinetics/toxicity
  • Middle Aged
  • Temporal Lobe/pathology
  • Tomography
  • X-Ray Computed
Affiliation entities Not a UNIGE publication
Citation (ISO format)
WEIGEL, Ralf et al. Severe complications after intrathecal methotrexate (MTX) for treatment of primary central nervous system lymphoma (PCNSL). In: Clinical Neurology and Neurosurgery, 2004, vol. 106, n° 2, p. 82–87. doi: 10.1016/j.clineuro.2003.09.005
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
Journal ISSN0303-8467
369views
0downloads

Technical informations

Creation08/04/2019 15:12:00
First validation08/04/2019 15:12:00
Update15/03/2023 16:06:51
Status update15/03/2023 16:06:50
Last indexation09/12/2024 15:16:45
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack